Modelling the natural history of Huntington's disease progression. Issue 10 (16th December 2014)

• Record Type: Journal Article
• Authors: Kuan, W L; Kasis, A; Yuan, Y; Mason, S L; Lazar, A S; Barker, R A; Goncalves, J
• Is Part Of: Journal of neurology, neurosurgery and psychiatry. Volume 86:Issue 10(2015)
• Page Start: 1143
• Page End: 1149
• Publication Date: 2014-12-16
• Subjects: HUNTINGTON'S -- MOVEMENT DISORDERS -- CLINICAL NEUROLOGY -- STATISTICS; Neurology -- Periodicals; Nervous system -- Surgery -- Periodicals; Psychiatry -- Periodicals; 616.8
• DOI: 10.1136/jnnp-2014-308153
• Languages: English
• ISSNs: 0022-3050

Abstract

Abstract : Background: The lack of reliable biomarkers to track disease progression is a major problem in clinical research of chronic neurological disorders. Using Huntington's disease (HD) as an example, we describe a novel approach to model HD and show that the progression of a neurological disorder can be predicted for individual patients. Methods: Starting with an initial cohort of 343 patients with HD that we have followed since 1995, we used data from 68 patients that satisfied our filtering criteria to model disease progression, based on the Unified Huntington's Disease Rating Scale (UHDRS), a measure that is routinely used in HD clinics worldwide. Results: Our model was validated by: (A) extrapolating our equation to model the age of disease onset, (B) testing it on a second patient data set by loosening our filtering criteria, (C) cross-validating with a repeated random subsampling approach and (D) holdout validating with the latest clinical assessment data from the same cohort of patients. With UHDRS scores from the past four clinical visits (over a minimum span of 2 years), our model predicts disease progression of individual patients over the next 2 years with an accuracy of 89–91%. We have also provided evidence that patients with similar baseline clinical profiles can exhibit very different trajectories of disease progression. Conclusions: This new model therefore has important implications for HD research, most obviously in the development of potential disease-modifying therapies. We believe that a similar approach can also be adapted to model disease progression in other chronic neurological disorders.